Clinical Research

“No great discovery was ever made without a bold guess,” Sir Isaac Newton

There’s an urgent need to find answers for the more than one million people living with progressive MS

As researchers, we know how exciting it is when this axiom comes true, especially when...

Clinical Research, Laboratory Research

New iPad App Tracks MS Patient Course

Researchers at the University of California, San Francisco, have developed a new tool that allows clinicians to track an individual’s disease course over time and compare it to a core data set of other MS patients. The tool is currently in beta-testing at UCSF.

Pierre-Antoine Gourraud, Ph.D., of the University of California, San Francisco, and I huddled around his iPad and...

Clinical Research, People

MS Research Roundup: October 28, 2014

Rare Brain Disease Death Reported for Dimethyl Fumarate; Using Arms and Legs After Spinal Cord Injury; How to Sell Bogus Drugs

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, People

MS Research Roundup: October 22, 2014

A Better CRISPR Mouse; Number Needed to Treat; Ann Romney to Raise $50M for Neuroscience Research

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research

No Causal Link Found Between Vaccines and MS

A large case-control study showed no causal link between current vaccines and the risk of MS or other CNS demyelinating disease, but there was a short-term increased risk in younger patients

A large nested case-control study, published October 20 in JAMA Neurology, showed no...

Clinical Research

MS Family Planning 201: Breastfeeding, DMTs, and the Risk of Postpartum Relapse

The risk of relapse is higher in the postpartum period, but there are conflicting suggestions for women with MS about reducing this risk. Can exclusive breastfeeding alone prevent relapses? How soon after delivery should DMTs be reintroduced? Are any DMTs safe to take while breastfeeding?

For any parent, the first few months after delivery are tumultuous—adapting to a new...

Clinical Research

MS Research Roundup: October 3, 2014

Stem Cells Pass Safety Trials; Generic Similar to Copaxone; Epigenetic Differences in Monocytes and Macrophages; One Brain, Many Genomes

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Laboratory Research, Methods

Phase 2 Trial Suggests RPC1063 Is as Effective as—and Safer Than—Fingolimod

RPC1063, an experimental oral immunomodulator, is looking promising as it progresses through clinical testing. At the ACTRIMS-ECTRIMS meeting in September, Amit Bar-Or presented results of the phase 2 trial suggesting the drug is as effective as and safer than its counterpart, fingolimod.

RPC1063 may open the door to more convenient treatment options for relapsing-remitting MS, if...

Clinical Research, Drug Development

Is Cognitive MS a Distinct Entity?

A small subset of MSers present with cognitive symptoms as the predominant manifestation of the disease and maintain that symptom throughout the disease’s course

About half of patients who receive a diagnosis of multiple sclerosis experience cognitive problems, along with...

Clinical Research

159 Genetic Variants Now Known to Be Associated With MS

The International MS Genetics consortium recently identified more than 45 new genetic variants associated with susceptibility to multiple sclerosis, many of which are involved in brain function

The list of genetic variants associated with multiple sclerosis grew even longer earlier this year at the...

Clinical Research, Laboratory Research, Meetings

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

“No great discovery was ever made without a bold guess,” Sir Isaac Newton

New iPad App Tracks MS Patient Course

MS Research Roundup: October 28, 2014

MS Research Roundup: October 22, 2014

No Causal Link Found Between Vaccines and MS

MS Family Planning 201: Breastfeeding, DMTs, and the Risk of Postpartum Relapse

MS Research Roundup: October 3, 2014

Phase 2 Trial Suggests RPC1063 Is as Effective as—and Safer Than—Fingolimod

Is Cognitive MS a Distinct Entity?

159 Genetic Variants Now Known to Be Associated With MS

Pages

MSDF Footer

Search form

Clinical Research

Pages